Adage Capital Partners
MCRB icon

Adage Capital Partners’s Seres Therapeutics MCRB Stock Holding History

Adage Capital Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,000
Closed -$2.14M – 1119
2022
Q1 		$2.14M Buy
15,000
+8,750
+140% +$1.35M ﹤0.01% 896
2021
Q4 		$1.04M Buy
+6,250
New +$993K ﹤0.01% 896

Other funds holding MCRB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Adage Capital Partners's MCRB Position: Q2 2022 in Review

Adage Capital Partners sold out of Seres Therapeutics (MCRB) in Q2 2022, closing a stake of 15,000 shares — an estimated $2.14M sold.

Adage Capital Partners first reported a position in MCRB in Q4 2021 and held it in 2 quarters. The position peaked at $2.14M in Q1 2022. 123 funds tracked by Wall St. Rank hold MCRB as of Q2 2022.

  • Adage Capital Partners reported no remaining Seres Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Adage Capital Partners sold 15,000 Seres Therapeutics shares in Q2 2022, an estimated $2.14M.
  • Adage Capital Partners first reported a position in Seres Therapeutics in Q4 2021 and held it in 2 quarters.
  • Adage Capital Partners's Seres Therapeutics position peaked at $2.14M in Q1 2022.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2022.

Based on Adage Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.